LLY
New access play, same Lilly ambition
Eli Lilly is rolling out the Lilly Change the Course Commitment, a global health initiative aimed at treating as many people with diabetes and obesity in low- and middle-income countries as in wealthier markets by 2040. That’s a very Lilly way of saying: the company wants its medicines to travel a lot farther than they do now.
Why this matters
The company says only one person in LMICs can access its medicines for every four in high-income countries, and it wants to close that gap through three moves:
- clinical development built for resource-limited settings
- registering medicines in more countries, especially across Africa, Latin America, and Asia
- strengthening local health systems so the drugs can actually reach people
For investors, this is less about a quick revenue pop and more about building the runway for a much bigger future market. If obesity and diabetes drugs become a global category, Lilly wants to be the first name people think of, not the one catching up later.
Foundayo gets the spotlight
The company also used the announcement to flex Foundayo (orforglipron), its oral treatment that can be stored at room temperature. That’s a pretty useful detail when you’re trying to scale in places where cold-chain logistics can be a headache and a half.
Lilly says the commitment follows its earlier 30×30 initiative, which reached 40 million people in resource-limited settings in 2025 — five years ahead of plan. So yes, this is part charity, part strategy, part “we’d like to own the next decade of global metabolic medicine.”
Big picture
This isn’t the kind of announcement that moves a stock on Tuesday morning by itself. But it does reinforce Lilly’s ambition to turn obesity and diabetes treatment into a worldwide franchise, and that’s the sort of long-term narrative investors love to argue about over coffee.